
Boost your antibodies’ potency with our GlymaxX® ADCC enhancement technology
In more than 15 years, ProBioGen has developed over 300 stable cell lines for clients in biotech and big pharma, tackling anything from antibodies over bispecific antibodies to some of the most challenging biosimilar recombinant proteins. Thanks to our extensive expertise in upstream and downstream development, we know all the pitfalls and can therefore deliver exceptional and timely results based on a proven and sophisticated process.
Applying our own CHO.RiGHT® expression vector technology and optimized signal sequences and genes, we select and assess clones under process conditions in our own chemically defined media platform. All final clones are confirmed for optimal cell-metabolic features and product quality, manufacturability, and stability, before Master Cell Bank (MCB) decision. A comprehensive cell line development report for Investigational New Drug (IND) filing is part of every project.
Our process is highly transparent and you will be informed about its progression at every stage.

Are you looking to enhance your program or would you like to learn more about our services?
Are you looking to enhance your program or are you just curious about our company, services, and technologies? Connect with our team and we will get back to you shortly.